实用医学杂志 ›› 2021, Vol. 37 ›› Issue (2): 205-209.doi: 10.3969/j.issn.1006⁃5725.2021.02.015

• 临床研究 • 上一篇    下一篇

SIRT1基因多态性对血糖控制不佳的2型糖尿病患者接受利拉鲁肽联合二甲双胍治疗效果的影响

高红红 ,任丽君, 马豪莉, 王利, 侯会娟 ,司马盼盼, 谢骅, 宋瑞捧   

  1. 河南省直第三人民医院内分泌科(郑州450002)
  • 出版日期:2021-01-25 发布日期:2021-01-25
  • 通讯作者: 宋瑞捧 E⁃mail:song.ruipeng1@163.com
  • 基金资助:
    河南省医学科技攻关计划项目(编号:2018020581)

Theeffect of SIRT1 gene polymorphism on the clinical efficacy of liraglutide combined with metformin in patients with type 2 diabetes with poor glycemic control 

GAO Honghong,REN Lijun,MA Haoli,WANG Li,HOU Huijuan,SIMA Panpan,XIE Hua,SONG Ruipeng   

  1. Department of Endocrinology,He Nan Sheng Zhi San Yuan,Zhengzhou 450002,China

  • Online:2021-01-25 Published:2021-01-25
  • Contact: SONG Ruipeng E⁃mail:song.ruipeng1@163.com

摘要:

目的 本研究旨在探讨 SIRT1 基因多态性对血糖控制不佳的 2 型糖尿病患者接受利拉鲁肽 联合二甲双胍治疗临床疗效的影响。方法 研究纳入接受 2 型糖尿病治疗血糖控制不佳患者 216 例,采 用利拉鲁肽联合二甲双胍治疗方案,26 周后评价临床疗效,分析患者 SIRT1 基因多态性与疗效之间的关 系。结果 216 例患者接受 26 周利拉鲁肽联合二甲双胍治疗后,HbA1c、FPG、2h PG BMI 指标均明显下 降,且与治疗前相比差异有统计学意义(P < 0.05)。TC/CC 型患者 HbA1c、FPG、BMI、2h PG 各指标比 TT 患者下降更为明显,差异有统计学意义(P < 0.05)。SIRT1 基因多态性分析显示患者 Rs12778366 位点基因 型分布频率均符合哈迪温伯格平衡。另外对 145 例患者 STIR1 基因 mRNA 表达分析发现,TT 型患者 mRNA 表达水平也显著低于 TC/CC 型患者(P < 0.001)。结论 利拉鲁肽联合二甲双胍在治疗既往血糖控 制不佳的 2 型糖尿病患者中安全有效,且携带 C 等位基因的患者疗效更好;SIRT1 基因 Rs12778366 位点可 能通过影响SIRT1基因mRNA 的表达而影响利拉鲁肽联合二甲双胍的临床疗效。

关键词:

Abstract:

Objective To investigate the effect of SIRT1 gene polymorphism on the clinical efficacy of liraglutide combined with metformin in type 2 diabetes patients with poor glycemic control. Methods 216 type 2 diabetes patients with poor glycemic control were included. Patients were treated with liraglutide combined with metformin. After 26 weeks treatment,the clinical efficacy was evaluated,and the relationship between SIRT1 gene polymorphism and efficacy was analyzed. Results After 26 weeks of treatment with lialulutide combined with metformin,the indexes of HbA1c,FPG,2H PG and BMI of 216 patients were significantly decreased,and the differences were statistically significant compared with those before treatment(P < 0.05). The indexes of HbA1c FPG,BMI and 2h PG in TC/CC patients decreased more significantly than those in TT patients,and the differences were statistically significant(P < 0.05). The polymorphism analysis of SIRT1 gene showed that the genotype distri⁃ bution frequency of Rs12778366 was in line with hardy Weinberg equilibrium. In addition,the STIR1 mRNA expression analysis of 145 patients showed that the mRNA expression level of TT patients was also significantly lower than that of TC/CC patients(P < 0.001). Conclusions Lilarutide combined with metformin is safe and effective in patients with type 2 diabetes with poor glycemic control,and patients with C allele are more effective. Rs12778366 of SIRT1 gene may affect the clinical efficacy of lylalutide combined with metformin by affecting the mRNA expres⁃ sion of SIRT1 gene.

Key words: